Genocea Biosciences (NASDAQ:GNCA) was upgraded by investment analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The brokerage currently has a $3.00 price target on the biotechnology company’s stock. Needham & Company LLC’s target price points to a potential upside of 229.67% from the stock’s previous close.
Several other research firms have also recently commented on GNCA. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Monday, October 16th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $5.00 target price on shares of Genocea Biosciences in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Genocea Biosciences currently has a consensus rating of “Hold” and a consensus price target of $4.45.
Shares of Genocea Biosciences (NASDAQ:GNCA) opened at $0.91 on Tuesday. Genocea Biosciences has a one year low of $0.79 and a one year high of $7.29. The company has a market capitalization of $72.91, a P/E ratio of -0.42 and a beta of 1.56. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.55 and a current ratio of 1.55.
A number of large investors have recently made changes to their positions in the business. Ameriprise Financial Inc. boosted its holdings in Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 2,300 shares in the last quarter. GSA Capital Partners LLP bought a new position in Genocea Biosciences in the second quarter worth approximately $100,000. Rhumbline Advisers bought a new position in Genocea Biosciences in the second quarter worth approximately $157,000. New York State Common Retirement Fund bought a new position in Genocea Biosciences in the second quarter worth approximately $159,000. Finally, OxFORD Asset Management LLP bought a new position in Genocea Biosciences in the second quarter worth approximately $204,000. Institutional investors and hedge funds own 12.02% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Genocea Biosciences (GNCA) Stock Rating Upgraded by Needham & Company LLC” was posted by Stock Observer and is owned by of Stock Observer. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.thestockobserver.com/2018/02/06/genocea-biosciences-gnca-stock-rating-upgraded-by-needham-company-llc.html.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.